← Back to patent-cliff list
Traneurocin
Tier C — Watch / tradeTraneurocin
Neuroactiva Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：AMPAR
Indications (approved)：Alzheimer's disease, 冠状病毒感染, Respiratory tract infection, COVID-19, Severe acute respiratory syndrome, 神经变性, 神经炎症性疾病, Tau蛋白病
Regional status
US
Phase III
2020-11-01
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Traneurocin?
Approved indications include: Alzheimer's disease, 冠状病毒感染, Respiratory tract infection, COVID-19, Severe acute respiratory syndrome, 神经变性, 神经炎症性疾病, Tau蛋白病.
When does the Traneurocin patent expire?
No public expiry year is available for Traneurocin yet; this page updates once verified.
How do I get a quote for Traneurocin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06